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Abstract
Background: Robots offer an alternative, potentially advantageous method of providing repetitive, high-dosage,
and high-intensity training to address the gait impairments caused by stroke. In this study, we compared the
effects of the Stride Management Assist (SMA®) System, a new wearable robotic device developed by Honda
R&D Corporation, Japan, with functional task specific training (FTST) on spatiotemporal gait parameters in stroke
survivors.
Methods: A single blinded randomized control trial was performed to assess the effect of FTST and task-specific
walking training with the SMA® device on spatiotemporal gait parameters. Participants (n = 50) were randomly
assigned to FTST or SMA. Subjects in both groups received training 3 times per week for 6–8 weeks for a
maximum of 18 training sessions. The GAITRite® system was used to collect data on subjects’ spatiotemporal
gait characteristics before training (baseline), at mid-training, post-training, and at a 3-month follow-up.
Results: After training, significant improvements in gait parameters were observed in both training groups
compared to baseline, including an increase in velocity and cadence, a decrease in swing time on the impaired
side, a decrease in double support time, an increase in stride length on impaired and non-impaired sides, and an
increase in step length on impaired and non-impaired sides. No significant differences were observed between
training groups; except for SMA group, step length on the impaired side increased significantly during
self-selected walking speed trials and spatial asymmetry decreased significantly during fast-velocity walking trials.
Conclusions: SMA and FTST interventions provided similar, significant improvements in spatiotemporal gait
parameters; however, the SMA group showed additional improvements across more parameters at various
time points. These results indicate that the SMA® device could be a useful therapeutic tool to improve
spatiotemporal parameters and contribute to improved functional mobility in stroke survivors. Further research
is needed to determine the feasibility of using this device in a home setting vs a clinic setting, and whether
such home use provides continued benefits.
Trial registration: This study is registered under the title “Development of walk assist device to improve
community ambulation” and can be located in clinicaltrials.gov with the study identifier: NCT01994395.
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Introduction
Stroke is the leading cause of adult-onset disability. Re-
cent studies estimate that stroke affects about 795,000
people in the U.S. each year, resulting in a prevalence of
over 6.4 million stroke survivors [1, 2]. In the U.S.,
stroke results in an estimated annual cost of $53.9 bil-
lion, of which $36.5 billion reflects direct healthcare
costs and the remainder is due to loss of productivity
[3]. Recent statistics project an exponential increase in
the global burden of stroke in the decades to come, par-
ticularly in low and middle-income countries [4]. With
the high prevalence of stroke and costly demands of
care, determining the most effective and efficient
methods for stroke rehabilitation is critically important
to reduce the overall burden stroke places on the health-
care system and on individual lives.
The goal of post-stroke rehabilitation is to reintegrate
individuals back to their highest level of function for
employment and social and community participation
[5]. A large proportion of stroke survivors (up to 80 %)
experience considerable gait deficits, limiting their cap-
acity for community ambulation [6]. Studies have shown
that after stroke, individuals demonstrate changes in
two important gait parameters, velocity and symmetry.
Velocity is known to decrease, while spatial and tem-
poral gait parameters show pronounced asymmetries.
Gait velocity following stroke has been found to range
from 18 to 103 cm/s [7–10], whereas the average for
healthy adults is 140 cm/s [11]. More than 50 % of indi-
viduals with chronic disability after stroke are known to
exhibit temporal and spatial gait asymmetries [12].
Typical asymmetry characteristics after stroke include
larger swing time / smaller swing time and/or larger
stance time/ smaller stance time (i.e., temporal asym-
metry) [12–14] and a larger step length /smaller step
length (i.e., spatial asymmetry) [15].
A commonly expressed goal of stroke survivors is to
ambulate with a more normal gait pattern and increased
gait velocity [16]. In order to address this goal, gait train-
ing is typically a major part of the rehabilitation process.
Several studies provide evidence of significant progress in
gait velocity through physical therapy [6, 17–20]; how-
ever, there is limited evidence for significant improve-
ments in spatial and temporal asymmetries (i.e. cadence,
step time, step length, stride length, swing time, stance
time, and double support time) following the rehabilita-
tion process [21]. Gait asymmetry may have other long-
term health consequences due to the increased demand
placed on the non-paretic limb. Bringing individuals
closer to a symmetrical gait pattern could improve energy
efficiency, gait speed, and balance control, in addition to
decreasing the risk of falls, lower extremity musculoskel-
etal injury, and loss of bone mineral density in the paretic
limb [12, 21, 22].
Various methods and outcome measures have been
used to assess an individual’s gait characteristics, such
as picture video systems, Force Sensitive Resistor
(FSR)–based pressure mats, and force platforms [23].
The GAITRite® system is a computerized assessment
tool that utilizes an electronic walkway mat consisting
of pressure-sensitive pads. GAITRite software recreates
the steps an individual takes as they walk across the
mat and calculates several spatiotemporal parameters,
such as step length, swing time, and velocity. Use of the
GAITRite system in assessing individuals with stroke
has been shown to have strong inter- and intra-rater
reliability [24], in addition to good test-retest reliability
when assessing spatiotemporal parameters of gait, with
an intraclass correlation coefficient (ICC) in the range
of 0.69-0.99 [22, 25, 26]. As improving gait is one of the
main rehabilitation goals after stroke, an accurate and
reliable tool such as the GAITRite to assess gait charac-
teristics is vital in evaluating the effectiveness of differ-
ent treatment methods.
Recovery of gait function after stroke is thought to be
driven by neural plasticity, which refers to changes in
neuronal organization that allow recovery and func-
tional adaptations after an insult to the brain [27]. In
order to encourage neural plasticity, an individual
needs to be provided with experiences and practice that
allow learning and sensory input [28, 29]. Research has
shown that current rehabilitation strategies can provide
these experiences through high repetition, high inten-
sity, and task-oriented movements [27, 30–34]. Within
the last decade, an increasing amount of research and
development has focused on the use of robotics for
post-stroke rehabilitation. Robots can readily provide
repetitive, high-dosage, and high-intensity training [27,
35], while reducing the labor and manual burden on
therapists during the rehabilitation process [27]. Specif-
ically, in individuals with stroke, two different types of
robotic devices, end-effector and exoskeleton robots,
can effectively complement conventional physical ther-
apy to improve gait function [36]. The newly develop-
ing field of wearable robotics has the potential to
provide additional advantages such as being easily
transportable, more natural to use, and simple to con-
trol [37]. Wearable robots could be also used at home
as a therapeutic technology both for assisting individ-
uals with disabilities to perform activities of daily living
and a means to continue rehabilitation outside of a
formal clinical setting [38].
The Stride Management Assist (SMA®) System is a
new wearable robotic device developed by Honda R&D
Corporation®, Japan (Fig. 1a). The SMA® was developed
to enhance walking performance and to increase the
community mobility and social interaction in elderly
adults and patients with gait disorders [39–41]. The
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SMA® is worn around the hips and provides independ-
ent, active flexion and extension at each hip joint to as-
sist the user during ambulation. However, there is
limited evidence on the effect of such robotic exoskele-
tons on spatiotemporal gait characteristics, and very few
studies have looked at the impact of a robotic exoskel-
eton on walking performance in the mild-moderate
stroke population. In this study, we evaluate the effects
of using the SMA® during task-specific training, com-
pared to conventional physical therapy, in stroke
survivors.
This study is part of a larger clinical trial, which aims
to determine the impact of two different therapy ap-
proaches on various characteristics of gait, cortical drive
to lower limb muscles, functional walking endurance,
and functional balance in subjects with chronic stroke.
The purpose of this study was to determine the effects of
task-specific walking training with the SMA® device
(SMA) vs. Functional Task Specific Training (FTST) on
the spatiotemporal characteristics of gait in an outpatient
setting for individuals post stroke. The task-specific walk-
ing training focused primarily on gait training with SMA;
the FTST focused on addressing the individual patient’s
functional goals, as planned with the physical therapists.




This study was a randomized controlled trial compar-
ing the effects of task-specific walking training with
the SMA vs. FTST on spatiotemporal gait parameters.
Subjects in both groups received training 3 times per
week for 6–8 weeks, for a maximum of 18 training
sessions. Each session was directed by a licensed phys-
ical therapist and lasted 45 min. Gait assessments were
performed at visits 0 (baseline), 10 (mid-test) 18 (post-
test), and at 3 months (follow-up) after training. Par-
ticipants did not receive any other therapy sessions
during the 3-month follow-up period (see Fig. 2 for
study schematic).
Participants
A total of 50 eligible subjects (33 male and 17 female)
with chronic stroke (minimum time since stroke of one
year) were recruited for the study and were randomized
into either the SMA group (n = 25; 17 male and 8 fe-
male) or the FTST group (n = 25; 16 male and 9 female)
using a random number generator (Table 1). Study
inclusion criteria included being medically stable; an
age between 18 and 85 years; an initial gait speed be-
tween 0.4 to 0.8 m/s (limited community ambulator); a
score greater than 17 on the Mini-Mental State Exam-
ination (MMSE); an ability to sit unsupported for 30 s;
an ability to walk at least 10 m with maximum 1 person
assist; the ability to follow a 3-step command; and
physician approval for patient participation. Exclusion
criteria included serious cardiac conditions within the
last 3 months; severe arthritis or orthopedic problems
that limit lower extremity passive range of motion
(knee flexion contracture of >10°, knee flexion ROM
<90°, hip flexion contracture >25°, and ankle plantar
Fig. 1 a. Honda Stride Management Assist (SMA®) Device b. Assist torque curve during gait cycle. Solid line indicates the changes in flexion assist
torque and dotted line indicates changes in extension assist torque during gait cycle
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flexion contracture of >15°); pre-existing neurological
disorders such as Parkinson’s disease, Amyotrophic Lat-
eral Sclerosis (ALS), Multiple Sclerosis (MS), dementia;
history of major head trauma, lower extremity amputa-
tion, non-healing ulcers of a lower extremity, renal dia-
lysis or end stage liver disease; legal blindness or severe
visual impairment; pacemakers or metal implants in the
head region; usage of medications that lower seizure
thresholds; history of concussion in last 6 months;
pregnant, nursing, or planning a pregnancy; participa-
tion in another clinical trial that, in the opinion of the
Principal Investigator (PI), would likely affect the study
outcome or confound the results. All subjects provided
informed consent prior to participation in the study,
which was approved by the Northwestern University
Institutional Review Board. All study procedures were
carried in accordance with the standards listed in Dec-
laration of Helsinki, 1964.
Study settings
Subjects were recruited from the Chicago area. Based on
their convenience and ability to commute, subjects were
referred to one of the Rehabilitation Institute of Chicago
(RIC) outpatient stroke rehabilitation clinics, either in
downtown Chicago, or in the suburbs of Northbrook,
IL, or Willowbrook, IL. Training sessions were com-
pleted by licensed RIC clinical physical therapists.
Devices
The Stride Management Assist (SMA®) device is a ro-
botic exoskeleton developed by Honda R&D Corpor-
ation®, Japan; (http://corporate.honda.com/innovation/
walk-assist/) (Fig. 1a). This device provides independent
assistance with hip flexion and extension for each leg to
increase step length. The device weighs 2.8 kg, and has
two brushless DC motors running on a rechargeable
lithium ion battery. The SMA® actuators are equipped
with angle and current sensors to monitor the range of
motion (degrees) of the user’s hip joints and the torque
(Nm) generated by the SMA®. Assist torque generated
by the SMA® actuators is transmitted to the thighs via
thigh frames. A physical therapist operates the device
and can remotely change assist settings through software
on a tablet while the user is using the SMA.
The SMA® control architecture uses a mutual rhythm
scheme to influence the user’s walking patterns. Gait
rhythms are believed to be controlled by Central Pattern
Generator (CPGs)–neural networks that generate rhythmic
patterns of output, independent of sensory feedback
[42]. The SMA® control law uses neural oscillators in
conjunction with the user’s CPG to synchronize itself
with user input [43]. Angle sensors embedded in the
SMA® actuators detect the user’s hip joint angles
throughout the gait cycle. These angles are input to the
SMA® controller, which calculates hip joint angle sym-
metry. The SMA® then generates assist torques at spe-
cific instances during the gait cycle to regulate these
walking patterns.
Figure 1b shows the SMA® assist torque curve over-
laid to the indicated key phases of the gait cycle [44].
Walking is initiated by the subject. After initial contact,
the extensor torque initiates and reaches its peak just
before mid-stance. The SMA® then switches to flexion
assist during terminal stance. The flexor torque reaches
its peak around initial swing. Finally, the SMA®
Fig. 2 Study design schematic
Table 1 Demographic characteristics of all participants who
completed the study
Patient Demographics FTST (n = 25) SMA (n =25)
Age (Years) 62 ± 3 60 ± 2
Gender (Male/ Female) 16/9 17/8
Hemiparesis (Right / Left) 12/13 13/12
Post Stroke (years) 5.4 ± 0.8 7.1 ± 1.5
Initial Gait speed (m/sec) 0.65 ± 0.02 0.7 ± 0.03
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switches to extension assist during terminal swing, and
the cycle repeats. Peak torque values for flexion and ex-
tension ultimately depend on user input. While the
SMA is capable of outputting a maximum of 6 Nm of
assist torque, peak torque values are contingent upon
user hip joint dynamics determined from the angle sen-
sors. The SMA® automatically manipulates the walking
motion to increase walk ratio (step length/cadence)
providing torque assistance during hip flexion and
extension movements when walking is initiated. For
example, if the SMA® detects hip joint angle asym-
metry, then the SMA® assist pattern follows a more
flexion dominant curve (Fig. 1b) for the leg with shorter
stride length, in an attempt to better support the user.
Depending on user hip joint angles, the peak flexor
torque may be less than 6 Nm. The user has total con-
trol on how fast they walk. The SMA® is designed to
provide assistance only in the sagittal plane; however, it
does not restrict movement in other directions.
The SMA® device is available in 3 sizes: medium, large,
and X-large and is worn around the waist like a belt,
with the motors placed near the hips and frames around
the thighs. The device is simple to use in a clinical set-
ting, is easily adjustable to accommodate the require-
ments of each subject, and only one functional upper
limb is needed to put it on.
Interventions
Initial clinical evaluations of all participants, performed
by the physical therapist, included a general assessment
of strength, flexibility, balance, sensation, endurance,
transfers, and gait. All training sessions were 45 min
long (in line with traditional physical therapy practice
guidelines) and were split into 3 units of 15 min. Split-
ting the therapy sessions into units is standard practice
in physical therapy clinics for the purposes of insurance
billing. However, the transition between units was seamless,
with rest breaks given as needed. General descriptions of
the two training groups are provided below:
Functional Task Specific Training (FTST)
FTST is a standard physical therapy training program
conducted at all clinics at the Rehabilitation Institute of
Chicago. The training program is based on the func-
tional goals of the stroke patient/subject, and is planned
in discussion with their physical therapist prior to begin-
ning of the therapy program. In this study, all partici-
pants chose improvement in gait function as their
functional goal. Each 45 min training session for the
FTST group comprised 15 min (1unit) of high intensity
over-ground walking training/ treadmill training at a
rated perceived exertion between 12–16 on a Borg Rate
of Perceived Exertion Scale (RPE, range 6–20) or 75 %
of age-predicted maximum heart rate (HRmax), followed
by 30 min (2 units) of functional goal-based mobility
training (based on subject’s functional goals). As all the
subjects in this group indicated improved gait function
as their primary functional goal, the functional gait train-
ing included walking on varied surfaces, multi directional
stepping, stair climbing, dual tasking, obstacles, and com-
munity mobility (walking outside the clinic in and around
the community).
Task-specific walking training using the SMA® (SMA)
The SMA group training sessions consisted of 30 min (2
units) dedicated to high intensity over-ground walking
training with SMA® (RPE: 12–16 or 75 % of HRmax),
and 15 min (1 unit) of dynamic functional gait training
with the SMA® (walking on varied surfaces, multi direc-
tional stepping, stair climbing, dual tasking, obstacles,
community mobility, etc.).
Outcome measures and baseline tests
All participants were evaluated by a research physical
therapist, who was blinded to the participant’s training
group. Gait analysis assessments were performed at the
beginning of the study (baseline), mid-point (mid), and
end (post) of the training sessions, and at a follow-up as-
sessment 3 months later. The GAITRite®, a system used
to measure and analyze various spatiotemporal aspects
of gait, comprises an electronic walkway with a
pressure-sensitive mat (asensor-rich area 36” wide and
202” long, with a spatial resolution of 0.5”). The system
records an individual’s footfalls as they walk over it, and
calculates gait parameters. Data were recorded at a sam-
pling rate of 120Hz. During data acquisition, participants
were allowed to wear their regular footwear, use their as-
sistive device if necessary, and received only stand-by as-
sist from the physical therapist when needed, to avoid
undue influence on subjects’ gait patterns. Participants
began walking approximately five feet before the start of
the walkway, and continued walking five feet beyond it,
to ensure time and space for acceleration and deceler-
ation. Each subject performed a total of 6 passes (3
passes at their normal self-selected pace and 3 passes at
their fastest possible pace) on the walkway during each
testing session. Footfalls recorded during each pass were
visually checked for completeness and automatically
processed to remove imprints from assistive devices
such as a cane, walker, etc. Gait parameters were esti-
mated for each pass separately and average values for
self-selected and fast-pace velocity trials at each assess-
ment point were used for further analysis.
For this study, gait velocity, cadence, step time, step
length, stride length, swing time, stance time, and double
support time were determined. These gait parameters
were used to manually calculate spatiotemporal asym-
metries. Spatial asymmetry was calculated by finding the
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ratio of right step length to left step length, while tem-
poral asymmetry was calculated by finding the ratio of
right to left swing time [21, 22, 45]. The larger value,
whether right or left, was always placed in the numer-
ator to produce a ratio greater than or equal to 1.0. A
ratio of 1.0 would indicate perfect symmetry between
the right and left legs. Bilateral gait parameters such as
step time, step length, stride length, swing time, stance
time, and double support time were further grouped into
impaired and non-impaired sides for further analysis and
to better understand the effects of training.
Data and statistical analysis
All values are presented as mean ± standard error of
mean (SEM), and the alpha value was set at p < 0.05 to
indicate statistical significance, unless noted otherwise.
The differences in baseline gait parameters between
groups (FTST and SMA) were compared using analysis
of variance. Two-way repeated measures ANOVA was
used to compare changes from baseline to the different
assessment points between the groups. Bonferroni post-
hoc pairwise comparisons were made to determine the
significance of differences, when applicable. Within each
group, paired t-tests were used to compare data from
different assessment points. Comparisons were made
between the baseline values and mid, post, and follow-
up time points and also between mid and post time
points. Bonferroni corrections were applied to account
for multiple comparisons (α = 0.0083). Sigmaplot 11.0
(Systat Software Inc., San Jose, CA, USA) was used to
perform all statistical analyses.
Results
A total of 54 subjects were consented for the study, and
50 completed all 18 training sessions and subsequent as-
sessments. Four participants dropped out prior to start-
ing the study due to transportation issues and scheduling
conflicts. No adverse events were reported during the
entire duration of the study.
Comparison of baseline data between test groups
Analysis of variance tests were used to compare baseline
data for all outcome measures between FTST and SMA
groups. No statistical difference in baseline measures was
observed between the FTST and SMA training groups.
Comparison of effects of training between test groups
during assessments
The average values for all gait parameters at baseline
and the change from baseline at each subsequent test-
ing point are presented in Table 2. In the SMA group,
step length values on the impaired side during the self-
selected walking speed trials were significantly longer,
and spatial asymmetry during fast-walking speed trials
was significantly lower than in the FTST group. No
other significant differences between groups were ob-
served during either self-selected velocity or fast-velocity
trials.
Effects of SMA and FTST training on gait parameters
Both the SMA and FTST training groups showed sig-
nificant within-group improvements in numerous gait
parameters, which are indicated in Tables 3 and 4,
where ‘Yes’ indicates significant improvements and ‘No’
indicates no significant change.
However, within the SMA group, significant improve-
ments in additional spatiotemporal variables were ob-
served compared to the FTST group. Those additional
improvements are discussed below, in comparison to
results from the FTST group.
Gait velocity
In self-selected walking velocity trials, significantly
improved gait speeds were achieved in both groups.
Both groups had statistically significant increases in
walking speed at mid-, post- and follow-up testing
compared to baseline values. However, in addition, in
the SMA group, significant improvements were also
observed between mid- and post-test walking speed
velocity (p <0.008).
In fast-velocity walking trials, both groups showed sig-
nificant increases in gait velocity at mid-, post-, and
follow-up testing compared to baseline and between the
mid- and post-testing time points (p <0.008).
Cadence
During self-selected walking speed trials, a significant in-
crease in cadence was observed only at post-test com-
pared to baseline (p < 0.008) in the FTST group. However,
in the SMA group, significant changes were also seen at
mid- and post-test compared to baseline (p <0.008).
For fast-walking trials, the FTST group had a signifi-
cant increase in cadence at post-test compared to base-
line (p < 0.008) and between post- and mid-test (p
<0.008). In the SMA group, cadence at mid-, post- and
follow-up testing was also significantly increased over
baseline (p <0.008).
Step time
In self-selected walking velocity trials, step times were
significantly lower at post-test compared to baseline on
the impaired side in both the training groups (p < 0.008).
On the non-impaired side, for the FTST group, step
times were significantly lower at the post-test when
compared to baseline (p <0.008). However, non-impaired
step times were significantly lower at both mid- and
post-tests compared to baseline only in the SMA group
(p <0.008).
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Table 2 Spatiotemporal characteristics at baseline and changes from baseline at mid, post and follow up assessments
Gait Parameter FTST SMA p value
Mid Post 3Mo. Follow up Mid Post 3Mo. Follow up
Velocity (Cm/s)
Self-Selected Velocity (SSV)- Baseline 64.61 ± 2.75 69.91 ± 3.03 0.205
Change from Baseline 5.17 ± 1.59 24.1 ± 5.07 10.25 ± 3.22 8.87 ± 2.59 17.41 ± 2.23 19.16 ± 4.37
Fast Velocity (FV) - Baseline 88.74 ± 3.79 95.51 ± 4.25 0.243
Change from Baseline 12.14 ± 3.12 20.13 ± 3.37 18.28 ± 3.12 17.62 ± 3.13 27.80 ± 3.17 20.96 ± 4.45
Cadence (Steps/min)
SSV trial- Baseline 90.20 ± 2.81 88.42 ± 2.50 0.638
Change from Baseline 2.59 ± 1.41 7.71 ± 2.27 3.0 ± 2.03 4.18 ± 1.4 7.25 ± 1.19 −1.4 ± 6.22
FV trial - Baseline 104.89 ± 3.28 104.99 ± 3.94 0.845
Change from Baseline 4.77 ± 2.22 8.89 ± 2.13 5.19 ± 2.57 8.94 + 1.84 13.17+ 2.47 11.75 + 2.52
Step Time (sec)
SSV trial - Impaired side Baseline 0.81 ± 0.03 0.82 ± 0.03 0.754
Change from Baseline −0.02 ± 0.01 −0.06 ± 0.02 −0.04 ± 0.02 −0.04 ± 0.01 −0.08 ± 0.01 −0.05 ± 0.02
SSV trial - Non impaired side Baseline 0.55 ± 0.02 0.56 ± 0.02 0.796
Change from Baseline −0.01 ± 0.01 −0.04 ± 0.01 −0.01 ± 0.01 −0.02 ± 0.01 −0.04 ± 0.01 −0.02 ± 0.01
FV trial - Impaired side Baseline 0.69 ± 0.02 0.68 ± 0.03 0.950
Change from Baseline −0.03 ± 0.01 −0.06 ± 0.01 −0.05 ± 0.02 −0.05 ± 0.01 −0.08 ± 0.01 −0.07 ± 0.01
FV trial - Non impaired side Baseline 0.49 ± 0.02 0.49 ± 0.02 0.869
Change from Baseline −0.02 ± 0.01 −0.03 ± 0.01 −0.03 ± 0.01 −0.04 ± 0.01 −0.05 ± 0.01 −0.04 ± 0.01
Stance Time (sec)
SSV trial - Impaired side Baseline 0.87 ± 0.03 0.86 ± 0.03 0.801
Change from Baseline −0.03 ± 0.02 −0.08 ± 0.02 −0.05 ± 0.02 −0.05 ± 0.02 −0.09 ± 0.01 −0.05 ± 0.02
SSV trial - Non impaired side Baseline 1.03 ± 0.03 1.03 ± 0.03 0.975
Change from Baseline −0.04 ± 0.02 −0.09 ± 0.02 −0.06 ± 0.02 −0.06 ± 0.02 −0.05 ± 0.02 −0.09 ± 0.02
FV trial - Impaired side Baseline 0.72 ± 0.02 0.71 ± 0.02 0.415
Change from Baseline −0.03 ± 0.02 −0.07 ± 0.01 −0.06 ± 0.02 −0.06 ± 0.01 −0.09 ± 0.01 −0.07 ± 0.01
FV trial - Non impaired side Baseline 0.86 ± 0.03 0.84 ± 0.03 0.715
Change from Baseline −0.04 ± 0.02 −0.08 ± 0.02 −0.07 ± 0.02 −0.08 ± 0.01 −0.11 ± 0.01 −0.08 ± 0.01
Swing Time (sec)
SSV trial - Impaired side Baseline 0.49 ± 0.02 0.52 ± 0.02 0.204
Change from Baseline −0.002 ± 0.01 −0.02 ± 0.01 −0.003 ± 0.01 −0.016 ± 0.01 −0.026+ 0.01 −0.016+ 0.02
SSV trial - Non impaired side Baseline 0.32 ± 0.01 0.35 ± 0.01 0.108
Change from Baseline 0.005 + 0.004 −0.004 + 0.01 0.011 ± 0.01 0.001 + 0.004 0.002 ± 0.01 0.013 ± 0.01
FV trial - Impaired side Baseline 0.45 ± 0.02 0.47 ± 0.02 0.472
Change from Baseline −0.01 ± 0.01 −0.02 ± 0.01 −0.10 ± 0.02 −0.03 ± 0.01 −0.04 ± 0.01 −0.13 ± 0.02
FV trial - Non impaired side Baseline 0.31 ± 0.01 0.33 ± 0.01 0.135
Change from Baseline −0.001 ± 0.01 −0.004 ± 0.01 0.03 ± 0.02 −0.01 ± 0.006 −0.01 ± 0.01 −0.01 ± 0.02
Double Support Time (sec)
SSV trial - Impaired side Baseline 0.55 ± 0.02 0.52 ± 0.02 0.337
Change from Baseline −0.04 ± 0.01 −0.08 ± 0.02 −0.06 ± 0.02 −0.05 ± 0.01 −0.1 ± 0.01 −0.06 ± 0.01
SSV trial - Non impaired side Baseline 0.55 ± 0.02 0.51 ± 0.02 0.288
Change from Baseline −0.04 ± 0.01 −0.08 ± 0.02 −0.06 ± 0.02 −0.05 ± 0.01 −0.1 ± 0.01 −0.06 ± 0.01
Buesing et al. Journal of NeuroEngineering and Rehabilitation  (2015) 12:69 Page 7 of 14
In fast-velocity walking trials, the FTST group showed
significantly lower step times at post-test compared to
baseline and mid-test for the impaired side (p <0.008),
and on the non-impaired side, post-test values were
lower than baseline (p < 0.008). However, the SMA
group had significantly lower step times at mid-, post-,
and follow-up testing compared to baseline in both
impaired and non-impaired sides (p <0.008).
Stance time
In self-selected walking speed trials, the FTST group
showed significant reduction in stance time on both the
impaired and non-impaired sides at post-test compared
to baseline (p < 0.008). However, for the SMA group, a
decreased stance time was observed at mid-, post- and
follow-up testing on both the impaired and non-impaired
sides (p <0.008). Furthermore, a significant decrease was
identified between mid- and post-test stance times on the
non-impaired side (p <0.008).
During fast-velocity walking trials, the FTST group had
significantly shorter stance times at post- and follow-up
testing compared to baseline on both the impaired and
non-impaired side. In addition, the non-impaired side also
had a significant decrease at post- compared to mid-test
values (p < 0.008). However, in the SMA group, stance
time decreased significantly at mid-, post- and follow-up
testing compared to baseline on both the impaired and
non-impaired sides (p < 0.008).
Table 2 Spatiotemporal characteristics at baseline and changes from baseline at mid, post and follow up assessments (Continued)
FV trial - Impaired side Baseline 0.41 ± 0.02 0.38 ± 0.02 0.234
Change from Baseline −0.03 ± 0.01 −0.06 ± 0.01 −0.06 ± 0.01 −0.05 ± 0.01 −0.08 ± 0.01 −0.05 ± 0.01
FV trial - Non impaired side Baseline 0.41 ± 0.02 0.38 ± 0.02 0.238
Change from Baseline −0.03 ± 0.01 −0.06 ± 0.01 −0.06 ± 0.01 −0.05 ± 0.01 −0.08 ± 0.01 −0.05 ± 0.01
Step Length (cm)
SSV trial - Impaired side Baseline 48.09 ± 1.6 50.37 ± 2.19 0.411
Change from Baseline 2.41 ± 0.79 4.89 ± 1.19 3.55 ± 1.57 4.21 ± 1.08 8.55 ± 1.14 6.27 ± 1.14
SSV trial - Non impaired side Baseline 38.36 ± 1.95 44.26 ± 2.13 0.051
Change from Baseline 2.28 ± 0.66 5.95 ± 1.26 6.43 ± 1.46 3.11 ± 0.86 6.54 ± 1.33 4.97 ± 1.76
FV trial - Impaired side Baseline 55.98 ± 0.19 58.70 ± 2.43 0.389
Change from Baseline 4.07 ± 0.96 5.69 ± 1.30 5.68 ± 1.68 5.13 ± 0.94 7.96 ± 1.12 2.18 ± 3.93
FV trial - Non impaired side Baseline 46.05 ± 2.10 51.92 ± 2.38 0.073
Change from Baseline 4.30 ± 1.07 7.29 ± 1.49 8.51 ± 1.83 4.12 ± 0.96 7.20 ± 1.28 3.66 ± 1.76
Stride Length (cm)
SSV trial - Impaired side Baseline 86.83 ± 2.93 94.76 ± 3.89 0.124
Change from Baseline 4.72 ± 1.21 10.61 ± 2.28 10.13 ± 2.95 8.14 ± 1.94 15.31 ± 2.15 11.67 ± 2.59
SSV trial - Non impaired side Baseline 86.80 ± 2.89 95.01 ± 3.88 0.135
Change from Baseline 4.72 ± 1.13 10.79 ± 2.27 10.02 ± 2.89 7.18 ± 1.78 14.93 ± 2.12 11.42 ± 2.67
FV trial - Impaired side Baseline 102.49 ± 3.14 110.86 ± 4.47 0.124
Change from Baseline 8.24 ± 1.77 12.9 ± 2.48 13.93 ± 3.21 9.47 ± 1.78 15.17 ± 2.22 9.997 ± 2.67
FV trial - Non impaired side Baseline 102.42 ± 3.14 111.09 ± 4.46 0.129
Change from Baseline 8.35 ± 1.80 12.75 ± 2.38 14.10 ± 3.22 8.98 ± 1.57 15.06 ± 2.09 9.85 ± 2.81
Spatial Asymmetry
SSV trial- Baseline 1.37 ± 0.08 1.25 ± 0.05 0.204
Change from Baseline −0.03 ± 0.05 −0.08 ± 0.04 −0.07 ± 0.04 0.002 ± 0.02 −0.01 ± 0.04 −0.06 ± 0.04
FV trial - Baseline 1.33 ± 0.07 1.19 ± 0.05 0.053
Change from Baseline −0.07 ± 0.03 −0.1 ± 0.04 −0.09 ± 0.04 −0.002 ± 0.02 −0.01 ± 0.03 0.04 ± 0.02
Temporal Asymmetry
SSV trial- Baseline 1.52 ± 0.05 1.50 ± 0.04 0.758
Change from Baseline −0.03 ± 0.02 −0.04 ± 0.03 −0.06 ± 0.02 −0.04 ± 0.02 −0.08 ± 0.02 −0.08 ± 0.04
FV trial - Baseline 1.44 ± 0.04 1.41 ± 0.04 0.654
Change from Baseline −0.02 ± 0.03 −0.05 ± 0.03 −0.04 ± 0.03 −0.05 ± 0.02 −0.08 ± 0.03 −0.04 ± 0.03
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Swing time
In self-selected walking speed trials, swing time decreased
significantly on the impaired side at post-test compared to
baseline value in the SMA group (p <0.008), while no sig-
nificant changes were observed in the FTST group.
In fast-velocity walking trials, swing time was signifi-
cantly decreased at follow-up compared to baseline on
the impaired side in the FTST groups (p < 0.008). In con-
trast, in the SMA group, significant decreases were ob-
served at mid-, post- and follow-up tests on the impaired
side (p < 0.008). Swing times at follow-up on the impaired
side were significantly lower compared to mid- and post-
test values in both groups (p < 0.008). No changes were
observed on non-impaired sides in either group.
Double support time
During self-selected walking speed trials, both training
groups had a significant decrease in double support time
at post-test compared to baseline in both the impaired
and non-impaired sides (p < 0.008). Additionally, the
SMA group had significantly lower values at mid- and
follow-up tests compared to baseline (p < 0.008) and a
significant decrease between mid- and post-test in both
the impaired and non-impaired side (p < 0.008).
Table 3 Within-group comparisons of spatiotemporal characteristics during self-selected velocity (SSV) walking trials: pre = baseline;
Mid = Mid-training test; Post = post-training test; Follow = follow-up test
Gait parameter Mid Vs. Pre Post Vs. Pre Follow Vs. Pre Post Vs. Mid Follow Vs. Mid Follow Vs. Post
SSV Velocity -FTST Yes Yes Yes No No No
SSV Velocity - SMA Yes Yes Yes Yes No No
SSV Cadence - FTST No Yes No No No No
SSV Cadence - SMA Yes Yes No No No No
SSV Step Time - Impaired - FTST No Yes No No No No
SSV Step Time - Impaired - SMA No Yes No No No No
SSV StepTime- Non Impaired - FTST No Yes No No No No
SSV StepTime- Non Impaired - SMA Yes Yes No No No No
Step Length- Impaired - FTST Yes Yes No No No No
Step Length- Impaired - SMA Yes Yes Yes Yes No No
Step Length - Non Impaired- FTST Yes Yes Yes No Yes No
Step Length - Non Impaired- SMA Yes Yes No No No No
Stride Length - Impaired - FTST Yes Yes Yes No No No
Stride Length - Impaired - SMA Yes Yes Yes Yes No No
Stride Length - Non Impaired - FTST Yes Yes Yes No No No
Stride Length - Non Impaired - SMA Yes Yes Yes Yes No No
SSV Swing Time - Impaired - FTST No No No No No No
SSV Swing Time - Impaired - SMA No Yes No No No No
SSV Swing Time - Non Impaired - FTST No No No No No No
SSV Swing Time - Non Impaired - SMA No No No No No No
SSV Stance Time - Impaired- FTST No Yes No No No No
SSV Stance Time - Impaired- SMA Yes Yes Yes No No No
SSV Stance time - Non Impaired- FTST No Yes No No No No
SSV Stance time - Non Impaired- SMA Yes Yes Yes Yes No No
SSV Double Supp. Time- Impaired - FTST No Yes No No No No
SSV Double Supp. Time- Impaired - SMA Yes Yes Yes Yes No No
SSV Double Supp. Time- Non Impaired - FTST No Yes No No No No
SSV Double Supp. Time- Non Impaired - SMA Yes Yes Yes Yes No No
SSV Spatial Asymmetry - FTST No No No No No No
SSV Spatial Asymmetry - SMA No No No No No No
SSV Temporal Asymmetry - FTST No No No No No No
SSV Temporal Asymmetry - SMA No Yes No No No No
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In fast-velocity walking trials, both training groups
showed a significant decrease in double support time at
post- and follow-up testing compared to baseline values
for both impaired and non-impaired sides (p <0.008).
Additionally, in the SMA group, a significant decrease was
also found at mid-test compared to baseline, and the de-
creases between mid- to post-test (both sides) and post-test
to follow up (impaired side) were significant (p < 0.008).
Step length
During self-selected walking speed trials, subjects showed
a significant increase in step length at mid- and post-tests
compared to baseline on the impaired side and non-
impaired sides in both training groups (p < 0.008). Add-
itionally, in the SMA group, a significant increase in step
length was also found at follow up vs. baseline and post vs.
mid time points on the impaired side. The non-impaired
side had significant increases at follow-up when compared
to both pre- and mid- values in the FTST group. (p < 0.008)
In fast-pace walking trials, the impaired side in both
groups showed an increase in step length at mid-, post-,
and follow-up tests from baseline level (p < 0.008). In
addition, in the SMA group, impaired-side step length
increased significantly from mid- to post-test (p < 0.008).
Table 4 Within-group comparisons of spatiotemporal characteristics during fast velocity (FV) walking trials: Pre = baseline; Mid =
mid-training test; Post = post-training test; Follow = follow-up test
Gait parameter Mid Vs. Pre Post Vs. Pre Follow Vs. Pre Post Vs. Mid Follow Vs. Mid Follow Vs. post
FV velocity - FTST Yes Yes Yes Yes No No
FV velocity - SMA Yes Yes Yes Yes No No
FV Cadence - FTST No Yes No Yes No No
FV Cadence - SMA Yes Yes Yes No No No
FV Step Time- Impaired - FTST No Yes No Yes No No
FV Step Time- Impaired- SMA Yes Yes Yes No No No
FV Step Time - Non Impaired- FTST No Yes No No No No
FV Step Time - Non Impaired- SMA Yes Yes Yes No No No
FV Step Length - Impaired- FTST Yes Yes Yes No No No
FV Step Length - Impaired- SMA Yes Yes Yes Yes No No
FV Step Length - Non impaired- FTST Yes Yes Yes Yes Yes No
FV Step Length - Non impaired- SMA Yes Yes No Yes No No
FV Stride Length - Impaired - FTST Yes Yes Yes No Yes No
FV Stride Length - Impaired- SMA Yes Yes Yes Yes No No
FV Stride Length - Non Impaired- FTST Yes Yes Yes No Yes No
FV Stride Length - Non Impaired- SMA Yes Yes Yes Yes No No
FV Swing time - Impaired- FTST No No Yes No Yes Yes
FV Swing time - Impaired- SMA Yes Yes Yes No Yes Yes
FV Swing time - Non Impaired-FTST No No No No No No
FV Swing time - Non Impaired-SMA No No No No No No
FV Stance Time - Impaired- FTST No Yes Yes No No No
FV Stance Time - Impaired- SMA Yes Yes Yes No No No
FV Stance Time - Non Impaired- FTST No Yes Yes Yes No No
FV Stance Time - Non Impaired-SMA Yes Yes Yes No No No
FV Double Supp. Time - Impaired- FTST No Yes Yes No No No
FV Double Supp. Time - Impaired- SMA Yes Yes Yes Yes No Yes
FV Double Supp. Time - Non Impaired-FTST No Yes Yes No No No
FV Double Supp. Time - Non Impaired-SMA Yes Yes Yes Yes No No
FV Spatial Asymmetry -FTST No No No No No No
FV Spatial Asymmetry -SMA No No No No No No
FV Temporal Asymmetry- FTST No No No No No No
FV Temporal Asymmetry- SMA No Yes No No No No
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On the non-impaired side, an increase in step length
was observed at mid-and post-tests compared to base-
line in both training groups. Additionally, the FTST
group showed significant increases in step length be-
tween baseline and follow-up, and mid-time points vs.
post and follow-up.
Stride length
During the self-selected walking speed trials, impaired
and non-impaired sides showed a significant increase in
stride length at mid-, post- and follow-up testing points
compared to baseline in both the FTST and SMA groups
(p < 0.008). In addition, in the SMA group, the increase
between mid- to post- was also significant on both sides
(p < 0.008)
Similar results were observed in fast-pace walking
trials, where both impaired and non-impaired sides
showed a significant increase in stride length at mid-,
post- and follow-up compared to baseline. Stride-length
in the FTST group also increased significantly from
mid- to follow-up values for both the impaired and
non-impaired sides. In the SMA group the increase ob-
served from mid- to post- was significant on both sides
(p < 0.008).
Spatial asymmetry
Although there were statistically significant differences
between groups, no statistically significant changes in
spatial asymmetry values were found within groups or
between sides (impaired vs. non-impaired), either during
self-selected or fast walking velocity trials.
Temporal asymmetry
Within the SMA group, a significant decrease in tem-
poral asymmetry was observed at post-testing com-
pared to baseline, for both self-selected and fast
walking velocity trials (p < 0.008). No significant de-
crease in temporal asymmetry was observed within the
FTST group.
Discussion
The results of this study show that short-term high-
intensity training using either a light-weight wearable
robot such as the SMA® or functional task-specific train-
ing can significantly impact spatiotemporal gait parame-
ters in individuals with chronic gait impairments due to
stroke. The only significant differences between training
groups were an increased step length on the impaired
side and reduction in spatial asymmetry within the SMA
training group. However, the change in spatial asym-
metry is more of a statistical change than a true clinical
change. For both groups, intensive training (3 times/
week) across groups over 6 weeks resulted in significant
improvements in numerous spatiotemporal parameters
of walking, specifically in: velocity, cadence, step time,
stance time, swing time, double support time, stride
length, and spatial asymmetry. This potentially demon-
strates that both interventions are beneficial for stroke
rehabilitation. However, the SMA® positively impacted
more gait variables measured at multiple time points,
showing that this device has promise as an appropriate
and effective therapeutic wearable robotic device for out-
patient rehabilitation. In addition, the SMA® is safe and
poses no risk to the user.
Using over-ground light-weight wearable robots to
target gait abnormalities is a relatively new concept,
and clinical research in this area is quite limited. Our
results are in line with the previous three studies on
the SMA® conducted in young adults and in the elderly,
where use of the SMA® resulted in positive changes in
gait performance. In the previous studies the changes
in gait performance were partially mediated by im-
provements in muscle activation, glucose metabolism,
and improved energy efficiency during use of the SMA®
[39, 40, 46]. Interestingly, several large studies using
treadmill-based robotic technology have found that
traditional physical therapy was a more effective inter-
vention for improving gait function following a stroke
than robotic technology [18, 47]. Results from our 50-
subject study indicate that wearable robots can poten-
tially provide improvements in gait function that are
superior or equal to high-intensity traditional physical
therapy. This finding may open up a field of research
on the therapeutic effects of over-ground robots, which
needs more extensive investigation.
One of the important variables we quantified in this
study was gait speed, an important ambulation param-
eter that is continually addressed after a stroke, as
improvements are known to directly impact quality of
life in stroke survivors [48]. Minimal clinically important
difference (MCID) for gait speed in the stroke popula-
tion ranges from 10 cm/s [49] to 16 cm/s [50]. MCIDs
are patient-derived scores that, following a clinical inter-
vention, reflect the minimum changes that are meaning-
ful for the patient. MCIDs are used in research and
clinical practice to make decisions on the therapeutic
gains made by the patient. Both the SMA and FTST
groups in this study showed increased gait speed above
the established MCID for stroke survivors in both post-
(SMA: fast velocity = 27.80 cm/s, self-selected velocity
= 17.41 cm/s; FTST: fast-velocity = 20.13 cm/s, Self-
selected velocity = 24.1 cm/s) and 3-month follow up
trials (SMA: Fast Velocity = 20.96 cm/s, self-selected
velocity = 19.16 cm/s; FTST: fast velocity = 18.28 cm/s,
self-selected velocity = 10.25 cm/s). Gait speed in our
study increased slightly more than has previously been
described [18]. Thus, both training interventions, when
performed at high intensity and dosage can have
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significant effects on gait within a short period of time
(six weeks). In addition, the SMA® may provide clini-
cians with the ability to continue physical rehabilitation
at home, as a take-home mobility device.
One possible explanation for the effect of SMA®
training on gait speed is that gait speed after stroke is
found to be impacted by the paretic side hip flexors,
which often compensate for plantar-flexor impairment
following stroke [51]. During late stance, the hip flexors
pull the leg upwards and forwards, advancing the leg
further before the subsequent heel strike, which con-
tributes to swing initiation [51]. Therefore it is possible
that stroke subjects with variable stepping on the par-
etic side have reduced paretic leg advancement during
swing due to impaired paretic leg hip flexor activity in
pre-swing. Therefore, an intervention that corrects for
this abnormality might help the hip-flexors in pre-
swing and subsequently help the leg to advance in
swing phase. This may be valuable in stroke rehabilita-
tion and lead to improvements in gait. In the current
study, the hip flexor/extensor assist provided by the
SMA® device may be a more effective intervention than
standard physical therapy training in targeting hip
flexor weakness on the paretic side.
To understand the impact of the SMA® on gait func-
tion we studied many other spatiotemporal parameters
impacted by stroke. Following a stroke, individuals
have a characteristic gait pattern that shows variable
step/stride length (shorter or longer) on the paretic
side compared to the non-paretic side, and a relatively
variable swing phase (longer or shorter) on the paretic
side compared to the non-paretic side [52]. This in-
creased variability in spatial and temporal variables
lead to poor dynamic balance and a decline in gait
speed and function.
In both the FTST and SMA groups, statistically sig-
nificant within-group changes in several parameters
(including cadence, swing time, double support time,
and stride length) with positive influences on gait
performance were seen across time. Cadence increased,
and an increase in the cadence of individuals post-
stroke is thought to demonstrate an improved gait per-
formance [53, 54]. Swing time was found to decrease
on the impaired side in both the FTST and SMA
groups. One typical characteristic of asymmetry seen in
individuals post-stroke is a variable swing time of the
paretic limb compared on the non-paretic limb (i.e.,
temporal asymmetry) [12–14]. As a result, a decrease
in swing time on the impaired side could indicate a
trend towards improved temporal asymmetry. Double
support time was found to decrease in both groups.
This too is considered an advantageous change in gait
because increased double support time has been shown
to lead to difficulty with balance and decreased energy
efficiency during ambulation [55]. Temporal asymmetry
in the SMA training group decreased in both fast and
self-selected velocity speeds. However, the observed
change of 0.08 in temporal symmetry for both walking
speeds does not seem to reach the MDC values pub-
lished in a manuscript by Lewek et al. [56]. Interest-
ingly, a greater number of spatiotemporal variables
improved in the SMA group over time than in the
FTST group; however, it is difficult to make any conclu-
sions on whether the SMA group is significantly better
than FTST based on these study data. Analysis of the
clinical, physiological, and community stepping data
from the larger data set of the full, ongoing clinical trial
will give us a better insight. Overall, our study indicates
that high-intensity training over just 18 sessions in both
the FTST and SMA groups improved spatiotemporal
gait parameters in individuals with stroke, with a trend
towards a more symmetrical and efficient gait pattern.
Bringing individuals closer to a symmetrical gait pat-
tern could impact energy efficiency, gait speed, and
balance control, and decrease the risk of falls, lower ex-
tremity musculoskeletal injury, and improve overall
quality of gait in the stroke population [22].
Some of the differences in performance noted be-
tween the SMA and the FTST groups likely result from
differences in the way each intervention targeted the
abnormal gait parameters. The SMA device functions
by generating assistance in active hip flexion and exten-
sion for each side independently. This group’s interven-
tion consisted of mainly high-intensity over-ground gait
training with some functional training. The FTST group
received no direct external robotic assistance with
ambulation; however, they additionally received high-
intensity treadmill training, combined with over-ground
gait and functional training.
Limitations
This study has a number of limitations including length
of study, and the SMA® device fit. The intervention was
limited to 6–8 weeks with a follow-up period of 3
months. The majority of timing effects were seen at
mid- to post-tests, indicating that an intervention
needed to take place for at least 6 weeks to be effective.
Determining whether the effects of these interventions
persist for longer than 3 months was beyond the scope
of this study, further research to determine the ideal
length of therapy to achieve long-lasting therapeutic
effects would be beneficial. Another limitation exists in
the fit accuracy of the SMA device to each individual
patient. Only standard sizes of the SMA device were
used, i.e., medium, large or extra-large. As for any orth-
otic, one size does not fit everyone, and a more cus-
tomized fit might have further enhanced outcomes in
the SMA users.
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Conclusions
In conclusion, a short time period (6 weeks) with 18
therapy sessions for both the SMA and FTST inter-
ventions provided similar, significant improvements in
a majority of spatiotemporal gait parameters, includ-
ing velocity, cadence, step time, stance time, swing
time, double support time, stride length, and spatial
asymmetry. However, the SMA® device was more ef-
fective at improving additional spatiotemporal param-
eters across different time points. Improvements in
these gait parameters can have a positive effect on
functional mobility and quality of life in stroke survi-
vors. The wearable over-ground robotic SMA® device
proved to be appropriate for gait training, safe, easy to
use, and posed no risk to users, indicating that it could
be safely implemented in a home setting. Further re-
search is needed to determine the importance of inter-
vention length and long-term effects, as well as the
feasibility of using this device in a clinic versus a home
setting.
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